Form 4: Provectus CEO Acquires Convertible Note, Sells Preferred

Provectus Biopharmaceuticals CEO Edward Pershing acquired a $70,000 convertible promissory note and disposed of 24,459 shares of Series D-1 Preferred Stock.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), acquired an 8% Unsecured Convertible Promissory Note with a principal amount of $70,000 on November 26, 2025.
• The Note is convertible into Series D-1 Convertible Preferred Stock at a price of $2.862 per share and will automatically convert on November 26, 2026.
• Pershing also disposed of 24,459 shares of Series D-1 Convertible Preferred Stock, valued at $1,345,000.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock and will automatically convert into Common Stock on June 26, 2026.
• The Note was issued pursuant to the Issuer's 2025 Financing.

Sentiment

Score: 5

Explanation: The acquisition of a convertible note by the CEO is a positive signal of confidence, but the simultaneous disposition of preferred stock introduces ambiguity. The complex conversion terms and timing discrepancies also add a neutral element, balancing the overall sentiment.

Positives

• The CEO's acquisition of an 8% Unsecured Convertible Promissory Note indicates continued investment and potential confidence in the company's future prospects.
• The '2025 Financing' suggests ongoing capital raising efforts to support company operations or strategic initiatives.

Negatives

• The disposition of 24,459 shares of Series D-1 Convertible Preferred Stock by the CEO, valued at $1,345,000, could be perceived negatively, potentially signaling a reduction in direct equity exposure or a move to de-risk personal holdings.
• The automatic conversion of Series D-1 Preferred Stock to Common Stock on June 26, 2026, occurs before the automatic conversion of the newly acquired convertible note into Series D-1 Preferred Stock on November 26, 2026, creating a complex and potentially confusing capital structure and conversion pathway for the new investment.

Risks

• The value of the convertible note and preferred stock is inherently tied to the future performance of the company's common stock.
• The complex and potentially conflicting conversion timelines for the convertible note and existing preferred stock introduce uncertainty regarding future equity structure and potential dilution for common shareholders.
• Insider dispositions, even if for personal reasons, can sometimes be interpreted by the market as a signal of reduced confidence in the company's short-to-medium term outlook.

Future Outlook

The filing indicates ongoing financing activities through the '2025 Financing' and outlines future conversion events for both the convertible note and preferred stock, suggesting a structured approach to capital management and potential future equity dilution. The timing discrepancies in conversion dates introduce complexity regarding the ultimate equity structure.

Management Comments

• The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note... at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock...
• The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock... on the date which is twelve months after the issue date of the Note.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock...
• The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless earlier converted...

Industry Context

Insider transactions, especially by top executives, are closely watched in the biotechnology and pharmaceutical sectors as they can signal management's confidence or concerns about pipeline progress, regulatory approvals, or commercialization prospects. Convertible notes are common financing instruments for growth-stage companies, offering flexibility while deferring immediate equity dilution.

Stakeholder Impact

• Shareholders: Potential for future dilution upon conversion of the note and preferred stock into common stock. The CEO's investment in the note could be seen as a positive signal, while the disposition of preferred stock could be seen as a negative signal, creating mixed perceptions.
• Creditors: The issuance of an 8% unsecured convertible promissory note adds to the company's debt obligations, though it also provides a pathway to equity conversion.

Next Steps

• Voluntary conversion of the 8% Unsecured Convertible Promissory Note into Series D-1 Convertible Preferred Stock.
• Automatic conversion of the 8% Unsecured Convertible Promissory Note into Series D-1 Convertible Preferred Stock on November 26, 2026.
• Voluntary conversion of Series D-1 Convertible Preferred Stock into Common Stock.
• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on June 26, 2026.

Key Dates

Recommendation

The CEO's acquisition of a convertible note demonstrates continued commitment, which is a positive indicator. However, the simultaneous disposition of a significant amount of preferred stock by the same executive introduces uncertainty and could be interpreted negatively by the market. The complex conversion structure and timing discrepancies between the note and preferred stock warrant a cautious 'hold' stance until further clarity on the executive's overall strategy and the company's financing plans emerges, allowing investors to assess the net impact on future equity value and dilution.

Keywords

Provectus Biopharmaceuticals, PVCT, Form 4, insider transaction, convertible note, preferred stock, CEO, Edward Pershing, beneficial ownership, 2025 Financing, equity